Cuba Presents Results of Anti-Lung Cancer Vaccine

Havana, Nov 22. -Experts from many nations on Tuesday are attending the 4th International Workshop on CIMAvax-EGF, an event where they will discuss the latest clinical results with this therapeutic vaccine to treat patients with non-small cell lung cancer.The forum, organized by the Molecular Immunology Center and the state-run CIMAB S.A. trade company, will assess how that drug performs in patients from Cuba and other countries where the medicine has been registered.

CIMAvax-EGF is the first vaccine against this kind of cancer in the world, and has been registered in Cuba, Canada, the United States, Japan and South Africa, among other countries, CIMAB S.A. general manager Norkis Arteaga told the press.

Cuba has achieved valuable results with that product, which does not cause severe secondary effects, provokes an immune response, and increases the survival of patients, improving their quality of life.

The meeting will be held on Wednesday at Havana´s Palco Hotel, in the presence of experts from Peru, Brazil, Argentina, Colombia, France, Belgium, Serbia, Korea and Germany. (Prensa Latina)